Back to results
US 2024/0083844 A1Published application
Kinase inhibitors and uses thereof
AssigneeABM Therapeutics Corporation
InventorChen CHEN
Life of this patent
Estimating the term…
Abstract
Provided are kinases inhibitors, pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions, such as methods of treating a proliferation disorder, such as a cancer or a tumor, or in some embodiments disease or disorders related to the dysregulation of kinase such as, but not limited to kinases such as MEK, COT1, FGFR4, MINK, MYO3A, PKG1B, and PLK3.
Claims53
A compound of Formula (I):
- or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof, wherein:
- G1 is CH or CR2
- G2, G3, and G4 are independently of each other N, CH, or CR2;
- provided that at least two of G2, G3, and G4 are independently of each other CH or CR2;
- and further provided that when G1 is CH, then at least one of G2, G3, and G4 is N or CR2;
- m is 0, 1, 2, 3, 4, or 5;
- p is 0, 1, 2, 3, or 4;
- q is 1, 2, or 3;
- each R1 is independently selected from the group consisting of halogen, OH, NH2, NO2, CN, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —O-[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —NH(optionally substituted C1-C6 alkyl), —N(optionally substituted C1-C6 alkyl)2, —NH[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —N[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)]2, —C(═O)-(optionally substituted C1-C6 alkyl), —C(═O)-(optionally substituted C2-C6 alkenyl), and —C(═O)-(optionally substituted C2-C6 alkynyl);
- each R2 is independently selected from the group consisting of halogen, OH, NH2, NO2, CN, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 haloalkyl, optionally substituted C1-C6 alkoxy, -[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —O-[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —NH(optionally substituted C1-C6 alkyl), —N(optionally substituted C1-C6 alkyl)2, —NH[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —N[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)]2, —C(═O)-(optionally substituted C1-C6 alkyl), —C(═O)-(optionally substituted C2-C6 alkenyl), and —C(═O)-(optionally substituted C2-C6 alkynyl);
- each R3 is independently selected from the group consisting of halogen, OH, NH2, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, -[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], optionally substituted C1-C6 alkylene-COOH, optionally substituted C1-C6 alkylene-C(═O)—O-(optionally substituted C1-C6 alkyl), optionally substituted C1-C6 alkoxy, —O-[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —NH(optionally substituted C1-C6 alkyl), —N(optionally substituted C1-C6 alkyl)2, —NH[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —N[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)]2, —C(═O)-(optionally substituted C1-C6 alkyl), —C(═O)-(optionally substituted C2-C6 alkenyl), and —C(═O)-(optionally substituted C2-C6 alkynyl);
- and
- R4 is selected from the group consisting of hydrogen, halogen, OH, NH2, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, -[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], optionally substituted C1-C6 alkylene-COOH, optionally substituted C1-C6 alkylene-C(═O)—O-(optionally substituted C1-C6 alkyl), optionally substituted C1-C6 alkoxy, —O-[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —NH(optionally substituted C1-C6 alkyl), —N(optionally substituted C1-C6 alkyl)2, —NH[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)], —N[(optionally substituted C1-C6 alkylene)-(optionally substituted C1-C6 alkoxy)]2, —C(═O)-(optionally substituted C1-C6 alkyl), —C(═O)-(optionally substituted C2-C6 alkenyl), and —C(═O)-(optionally substituted C2-C6 alkynyl).
10 more elements
A compound selected from a compound of Table 1:
- Compound
- No.
- Structure
- Chemical Name
- 1
- N-(azetidin-3-yl)-2,4- difluoro-6-((2-fluoro-4- iodophenyl)amino)benzamide
- 2
- 2,4-difluoro-6-((2-fluoro-4- iodophenyl)amino)-N- (pyrrolidin-3-yl)benzamide
- 3
- 2,4-difluoro-6-((2-fluoro-4- iodophenyl)amino)-N- (piperidin-3-yl)benzamide
- 4
- N-(azetidin-3-y1)-2,3,4,5- tetrafluoro-6-((2-fluoro-4- iodophenyl)amino)benzamide
- 5
- N-(azetidin-3-y1)-3-fluoro-5- ((2-fluoro-4-iodophenyl) amino)isonicotinamide
- 6
- N-(1-ethylazetidin-3-y1)-3- fluoro-5-((2-fluoro-4- iodophenyl)amino) isonicotinamide
- 7
- 3-fluoro-5-((2-fluoro-4- iodophenyl)amino)-N-(1- methylazetidin-3- yl)isonicotinamide
- 8
- 3-fluoro-5-((2-fluoro-4- iodophenyl)amino)-N-(1- isopropylazetidin-3- yl)isonicotinamide
- 9
- 3-fluoro-5-((2-fluoro-4- iodophenyl)amino)-N-(1-(2- fluoroethyl)azetidin-3- yl)isonicotinamide
- 10
- 3-fluoro-5-((2-fluoro-4- iodophenyl)amino)-N-(1-(2- methoxyethyl)azetidin-3- yl)isonicotinamide
- 11
- N-(azetidin-3-y1)-3-((4- ethyny1-2- fluorophenyl)amino)-5- fluoroisonicotinamide
- 12
- N-(1-ethylazetidin-3-y1)-3- ((4-ethynyl-2- fluorophenyl)amino)-5- fluoroisonicotinamide
- 13
- N-(azetidin-3-y1)-3-chloro-5- ((2-fluoro-4-iodophenyl) amino)isonicotinamide
- 14
- N-(azetidin-3-yl)-3-((4- bromo-2- chlorophenyl)amino)-5- fluoroisonicotinamide
- 15
- N-(azetidin-3-yl)-3-((2- fluoro-4- iodophenyl)amino) isonicotinamide
- 16
- N-(azetidin-3-yl)-4-((2- fluoro-4- iodophenyl)amino) nicotinamide
- 17
- 3-((4-acetyl-2- fluorophenyl)amino)-N- (azetidin-3-y1)-5- fluoroisonicotinamide
- 18
- 3-(3-(3-((2-fluoro-4- iodophenyl)amino)isonicotina mido)azetidin-1-yl)propanoic acid
- 19
- 4-(3-(3-((2-fluoro-4- iodophenyl)amino)isonicotina mido)azetidin-1-yl)butanoic acid
- 20
- N-(1-acetylazetidin-3-y1)-3- fluoro-5-((2-fluoro-4- iodophenyl)amino) isonicotinamide
- or a pharmaceutically acceptable salt, solvate or isotopic derivative thereof.
42 more elements
Dependencies are inferred from the claim text.